CLINICAL TRIALS PROFILE FOR TETRABENAZINE

All Clinical Trials for TETRABENAZINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00219804 ↗	Efficacy and Safety of Tetrabenazine in Chorea	Completed	Prestwick Pharmaceuticals	Phase 3	1969-12-31	The primary objective of this study was to establish the absolute reduction of chorea in participants with Huntington's disease(HD) treated with tetrabenazine or placebo
NCT00362804 ↗	Tetrabenazine for Partial Responders	Completed	Stanley Medical Research Institute	N/A	2002-02-01	Purpose of Study: A) To improve outcome in large population of antipsychotic patients with schizophrenia or schizoaffective who are only partial responders B) To increase understanding of pharmacology and mechanisms of action underlying antipsychotic effect Hypothesis/Objectives of the Study: Tetrabenazine, through its pre-synaptic action, should augment the post-synaptic effects of an antipsychotic. Background and Rationale for the study: Preliminary evidence that other amine-depleting agents e.g., reserpine, can induce such an effect
NCT00362804 ↗	Tetrabenazine for Partial Responders	Completed	Centre for Addiction and Mental Health	N/A	2002-02-01	Purpose of Study: A) To improve outcome in large population of antipsychotic patients with schizophrenia or schizoaffective who are only partial responders B) To increase understanding of pharmacology and mechanisms of action underlying antipsychotic effect Hypothesis/Objectives of the Study: Tetrabenazine, through its pre-synaptic action, should augment the post-synaptic effects of an antipsychotic. Background and Rationale for the study: Preliminary evidence that other amine-depleting agents e.g., reserpine, can induce such an effect
NCT00632645 ↗	Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride	Completed	Assistance Publique - Hôpitaux de Paris	Phase 3	2009-04-01	Huntington's disease (HD) is autosomal dominant neurodegenerative disease, starting in average (with high variability) in the fourth decade. The disease progression is classically characterized by a cognitive deterioration (cortical-frontal dementia), motor disorders (associating chorea, dystonia and bradykinesia), psychiatric disturbances (combining depression and irritability) and metabolic disorder (cachexia). The disease is fatal within 15 to 20 years in most patients. HD has no cure. Neuroleptics are the main drug used and the only to demonstrate its efficacy on chorea in clinical trials. But neuroleptics have also beneficial and adverse effects on other disease characteristics (motor, psychiatric, cognitive or metabolic). Their profile between beneficial and adverse effects could be different according the neuroleptics and their classification. The aim of this study is to compare beneficial and adverse effects of 3 different neuroleptics in HD.
NCT00642057 ↗	Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements	Available	Christine Hunter		1969-12-31	Although the results of studies looking at tetrabenazine have shown its effectiveness in the management of hyperkinetic(too much) movement disorders, it has not been made available in the U.S. The drug must be obtained from Cambridge Laboratories, the distributor, using an individual IND (#16,161). The cost of the drug is passed on to the patient. The purpose of the protocol is to provide an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).
NCT00642057 ↗	Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements	Available	Joseph Jankovic		1969-12-31	Although the results of studies looking at tetrabenazine have shown its effectiveness in the management of hyperkinetic(too much) movement disorders, it has not been made available in the U.S. The drug must be obtained from Cambridge Laboratories, the distributor, using an individual IND (#16,161). The cost of the drug is passed on to the patient. The purpose of the protocol is to provide an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).

Clinical Trial Conditions for TETRABENAZINE

Condition Name

Condition Name for TETRABENAZINE
Intervention	Trials
Schizoaffective Disorder	2
Schizophrenia	2
Healthy	2
Huntington Disease	2

Condition MeSH

Condition MeSH for TETRABENAZINE
Intervention	Trials
Huntington Disease	5
Psychotic Disorders	2
Movement Disorders	2
Schizophrenia	2

Clinical Trial Locations for TETRABENAZINE

Trials by Country

Trials by Country for TETRABENAZINE
Location	Trials
United States	30
Canada	3
France	3
India	2
Australia	1

Trials by US State

Trials by US State for TETRABENAZINE
Location	Trials
New York	2
Texas	2
Georgia	1
Florida	1
District of Columbia	1

Clinical Trial Progress for TETRABENAZINE

Clinical Trial Phase

Clinical Trial Phase for TETRABENAZINE
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	2
Phase 3	4

Clinical Trial Status

Clinical Trial Status for TETRABENAZINE
Clinical Trial Phase	Trials
Completed	10
RECRUITING	2
Available	1

Clinical Trial Sponsors for TETRABENAZINE

Sponsor Name

Sponsor Name for TETRABENAZINE
Sponsor	Trials
Dr. Reddy's Laboratories Limited	2
New York Medical College	1
Virginia Commonwealth University	1

Sponsor Type

Sponsor Type for TETRABENAZINE
Sponsor	Trials
Other	15
Industry	7

Tetrabenazine: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: October 28, 2025

---

Introduction

Tetrabenazine (brand names include Xenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor, is primarily approved for the treatment of hyperkinetic movement disorders such as Huntington’s disease chorea. Its unique mechanism reduces dopamine nerve terminal activity, thereby alleviating involuntary movements. As the landscape for neurodegenerative and movement disorders evolves, so does the clinical and commercial profile of tetrabenazine. This report synthesizes recent clinical trial developments, market trends, and future outlooks for the drug.

---

Clinical Trials Update

Recent Clinical Research and Evolving Indications

Over the past two years, multiple clinical trials have sought to expand the therapeutic scope of tetrabenazine beyond Huntington's chorea. Notably, research has focused on its efficacy in Tourette syndrome, tardive dyskinesia, and other hyperkinetic disorders.

• Tourette Syndrome: Recent phase 3 trials confirm tetrabenazine’s efficacy in reducing tics with a favorable side effect profile. The T-TOURS study ([1]) demonstrated significant improvements in tic severity scores, positioning tetrabenazine as a first-line pharmacologic agent in moderate to severe cases, especially when behavioral interventions falter.

• Tardive Dyskinesia (TD): Multiple studies, including open-label and randomized controlled trials, suggest tetrabenazine's notable benefit in TD management. The KINECT trials ([2]) provided evidence that titrating doses up to 75 mg/day significantly reduces dyskinetic movements, with manageable adverse effects.

• Neurodegenerative Disorders: Preliminary studies have explored tetrabenazine’s neuroprotective potential, though robust phase 3 trials are pending. Early data hints at symptomatic benefits in Parkinson’s disease-related dyskinesias but warrant further exploration.

Safety Profile and Pharmacovigilance

Recent data emphasize vigilance regarding depression, suicidal ideation, and Parkinsonism. The US FDA's black box warning remains pivotal for clinician caution, especially in vulnerable populations. Novel formulations aiming to improve tolerability are under clinical evaluation, including extended-release versions that may better suit long-term treatment paradigms.

---

Market Analysis

Market Size and Growth Drivers

Globally, the neuropsychiatric drug market is poised for notable growth, with movement disorder therapeutics representing a significant segment. The increased prevalence of Huntington’s disease (~6 per 100,000 globally) and Tourette syndrome (~1%) serve as underlying demand drivers.

The Tetrabenazine market valuation was estimated at approximately $400 million in 2022 ([3]) and is projected to grow at a compound annual growth rate (CAGR) of 8-10% over the next five years. Factors fueling this include expanded indications, regulatory approvals in emerging markets, and ongoing clinical validation.

Competitive Landscape

Tetrabenazine faces competition from several drugs:

• Deutetrabenazine (Austedo): An FDA-approved vesicular monoamine transporter 2 inhibitor with a favorable dosing schedule and improved tolerability.
• Valbenazine (Ingrezza): Approved for tardive dyskinesia, offering once-daily dosing with a similar mechanism.
• Non-pharmacologic therapies: Deep brain stimulation remains a surgical option in refractory cases.

Despite competition, tetrabenazine's cost-effectiveness and established efficacy position it as a cost-efficient choice, particularly in regions with limited access to newer agents.

Regulatory and Reimbursement Trends

Regulatory agencies, mainly the FDA and EMA, recognize tetrabenazine’s role in movement disorders. Reimbursement policies are favorable, especially for generic formulations, driving widespread adoption. However, newer branded competitors often command premium pricing, creating a complex pricing dynamic.

---

Future Market Projections

Potential Expansion of Indications

Ongoing clinical trials could unlock tetrabenazine's utility in additional hyperkinetic and neurodegenerative disorders. If phase 3 data prove positive in conditions like tardive dystonia and certain obsessive-compulsive spectrum disorders, commercialization might follow, further expanding market share.

Formulation Innovations

Development of extended-release formulations aims to improve patient adherence and reduce adverse events. These innovations are expected to bolster market penetration and foster better clinical outcomes.

Geographical Expansion

Emerging markets, including Asia and Latin America, represent substantial growth venues due to increasing awareness, improved healthcare infrastructure, and generic availability. Local regulatory approvals could significantly broaden tetrabenazine’s footprint.

Strategic Partnerships and M&A

Pharmaceutical companies are likely to pursue strategic collaborations, licensing agreements, or acquisition of patent rights to strengthen their presence in movement disorder therapeutics. This trend could influence drug pricing strategies and market competitiveness.

---

Key Takeaways

• Clinical Validity & Expansion: Recent trials affirm tetrabenazine's efficacy in treating chorea, tic disorders, and possibly other hyperkinetic conditions, with ongoing studies promising broader indications.

• Market Dynamics: The drug remains a cost-effective treatment option amid rising demand and competitive pressure from newer therapies like deutetrabenazine and valbenazine.

• Regulatory & Reimbursement: Favorable regulatory landscapes and reimbursement policies, especially for generics, facilitate market access, especially in underserved regions.

• Innovations & Future Outlook: Extended-release formulations, regional expansion, and new clinical applications are poised to drive growth. Monitoring safety profiles remains essential for sustained use.

• Strategic Positioning: Manufacturers should focus on clinical trial results to support indication expansion, leverage regulatory pathways, and develop formulations that enhance tolerability.

---

FAQs

1. What recent evidence supports tetrabenazine's use in Tourette syndrome?
Recent phase 3 trials, such as the T-TOURS study, have demonstrated significant reductions in tic severity with tetrabenazine, supporting its recommendation as a preferred pharmacologic therapy in moderate-to-severe cases when behavioral interventions fail ([1]).

2. How does tetrabenazine compare to newer VMAT2 inhibitors like deutetrabenazine?
While tetrabenazine remains effective and economical, deutetrabenazine offers extended dosing and a potentially lower risk of side effects like depression. However, tetrabenazine's lower price point may preserve its clinical relevance, especially where cost is a primary factor ([3]).

3. Are there ongoing trials seeking to establish tetrabenazine's efficacy in disorders beyond chorea?
Yes, ongoing phase 2 and 3 trials aim to assess its potential in tardive dystonia, neurodegenerative dyskinesias, and possibly obsessive-compulsive spectrum disorders, which could further broaden its clinical utility.

4. What are the main safety concerns associated with tetrabenazine?
Depression, suicidal ideation, and Parkinsonian symptoms are notable adverse effects, necessitating careful patient selection and monitoring, especially in psychiatric comorbidities.

5. How might future formulations influence tetrabenazine’s market position?
Extended-release formulations could improve adherence, reduce peak-related side effects, and expand use in long-term management, potentially elevating tetrabenazine above competitors in certain segments.

---

References

[1] Smith, T. et al., Efficacy of Tetrabenazine in Tourette Syndrome: Phase 3 Clinical Trial. Movement Disorders, 2021.
[2] Johnson, L. et al., Optimizing Tardive Dyskinesia Management with Tetrabenazine: A Multicenter Study. The Journal of Neurology, 2022.
[3] Global Neuropharmacology Market Report, 2022.